Fill in your details to access the 2020 sponsorship brochure, containing details of all our available commercial opportunities.

Leading partner

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

Presenting partner


Baere, Craft Consulting stands for creative, collaborative and solution-oriented policy making for the long term. With the financial support and input of Alnylam Pharmaceuticals, argenx, bluebird bio, Ultragenyx and Vertex – a group of research-driven companies that innovate in the field of severe, genetic and (ultra) rare diseases based on cutting-edge science – it drafted the reflection paper “Transformative policies for transformative medicines – Fast-tracking the biotech revolution for patients”. We work at the pioneering edge and in the highest risk areas of medical research with the aim to create new classes of medicines that can transform the lives of patients. We believe smaller companies like ours play the crucial role of engaging in the highly risky business of pushing the biopharmaceutical frontier further. None of the points of view expressed in this reflection paper can, however, be attributed to one particular firm.

For more information, visit www.baerecraft.com

Supporting partner

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit www.takeda.com

With the support of

The HealthManagement.org leadership community engages in cross-collaboration and promotes management, leadership, winning practices in healthcare. 

With the active engagement from thought leaders and almost 100 well-respected national and international associations and congresses, HealthManagement provides comprehensive information related to Executive Management, Imaging, Healthcare IT & Cardiology.

PharmaBoardroom is a global platform that connects the experiences and expertise of C-level executives throughout the world. Covering management strategy, regulatory reforms, R&D, market access and pricing, PharmaBoardroom offers a seat at the table with pharma leaders and decision makers. We do this by providing unparalleled content that informs, engages and inspires senior professionals to help them understand global trends and strategies and translate them into local realities.

Association Innovative Medicines

Association Innovative Medicines is the industry association for the Dutch branches of innovative pharmaceutical companies. The association is not active in the field of generic or non-prescription drugs but is strongly involved with companies focused on biotechnological medicines. The association promotes the interests of its more than 40 member companies. It follows government policy closely, responds proactively to plans and decisions. We contribute to the social debate to ensure a sustainable and future-proof healthcare system. The association collaborates with stakeholders, politicians and policy makers, and advocates policies which encourage outcomes-based healthcare, clinical research and innovation. The association provides information and advice using practical means such as meetings, brochures, websites, assists in legal matters, and has a weekly newsletter.

For more information, visit www.vereniginginnovatievegeneesmiddelen.nl